Compare DexCom, Inc. (DXCM) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lemonade Inc — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Lemonade Inc trades at $51.51 (market cap $4.09B). The key difference: DexCom, Inc. is far larger — about 8.3× Lemonade Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | LMND | |
|---|---|---|
Market Cap | $33.79B | $4.09B |
Sector | Health | Financials |
52-Week High | $89.53 | $96.57 |
52-Week Low | $54.84 | $47.38 |
Enterprise Value | $33.24B | $3.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Lemonade (LMND) trades at $51.63, down 1.99% on the day, with a bearish technical signal from moving averages. Revenue growth is strong, reaching $737.9M in 2025, but the company remains unprofitable with a net income margin of -14.19%. Recent Q2 2026 earnings beat expectations, and the company targets positive adjusted EBITDA by Q4 2026, yet the stock faces selling pressure amid valuation concerns.
The outlook hinges on Lemonade's path to profitability; achieving its EBITDA target could drive upside toward the $58 consensus price target. Key risks include persistent losses, competitive pressures, and execution challenges in scaling its AI-driven insurance model. Investor sentiment is divided, reflecting the high-growth but high-burn profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
